The aim of the study was to compare physical and biological dosimetry methods in iodine-131 (I-131)-receiving patients. The present study comprised of 47 patients (mean age: 47.9 ± 15.8 years), treated with I-131. Group I consisted of 17 patients with hyperthyroidism and mean administered activity of this group was 432.9 ± 111 MBq. There were 15 follow-up patients of differentiated thyroid cancer (DTC) in Group II with mean administered activity of 185 ± 22.2 MBq, who were administered scanning dose of I-131. Group III comprised of 15 patients with DTC, ablated with high-dose of I-131, and this group's mean administered activity was 4347.5 ± 695.6 MBq. The whole-body absorbed doses were calculated in all patients both with the Medical Internal Radiation Dosimetry (MIRD) method using MIRDOSE3 software and cytokinesis-block micronucleus (MN) assay-based MN analysis and were compared. The whole-body absorbed dose, calculated by MIRD method, showed very good correlation with the administered I-131 activity ( = 0.89, < 0.001), but it was moderate in the MN method ( = 0.52, < 0.01). Absorbed dose estimations with MIRD method were 49.2 ± 20.8 mGy in Group I, 6.5 ± 1.6 mGy in Group II, and 154.3 ± 47.8 mGy in Group III; the differences were statistically significant ( < 0.001), as expected. Pre- and posttreatment MN frequencies differed significantly in all groups ( < 0.05). The whole-body absorbed doses, based on MN method, were 68.2 ± 17.5, 46.0 ± 11.4, and 90.5 ± 26.9 mGy in Groups I-III, respectively. The difference was significant between Group II and Group III ( < 0.01). The mean absorbed dose was 74.6 ± 27.9 mGy with MN versus 68.0 ± 67.1 mGy in MIRD method ( = 0.087) in the entire study population and the correlation was moderate ( = 0.73, < 0.001). The whole-body absorbed doses, estimated by MN method, showed moderate correlation with administered radioiodine activities in low radioiodine doses and had significantly different and fluctuating values as compared to MIRD method in patients treated with I-131.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6216729PMC
http://dx.doi.org/10.4103/wjnm.WJNM_78_17DOI Listing

Publication Analysis

Top Keywords

mird method
20
whole-body absorbed
16
administered activity
12
group iii
12
absorbed doses
12
absorbed dose
12
mgy group
12
group
9
physical biological
8
biological dosimetry
8

Similar Publications

Purpose: To report outcomes in hepatocellular carcinoma (HCC) patients with lobar and segmental vascular invasion treated with resin Yttrium-90 transarterial radioembolization (Y90-TARE) with single-compartment MIRD (Medical Internal Radiation Dose) model.

Materials And Methods: This was a retrospective IRB approved study of patients with a diagnosis of HCC with vascular invasion undergoing resin Y90-TARE from 2014 to 2022 (n = 61). Patients with Body Surface Area dosimetry (n = 20), main portal vein invasion (n = 6) and patients with an ECOG of > 2 were excluded (n = 1) with a final cohort of 34 patients.

View Article and Find Full Text PDF

Background: Spinal pain affects up to 30% of school-age children and can interfere with various aspects of daily life, such as school attendance, physical function, and social life. Current assessment tools often rely on parental reporting which limits our understanding of how each child is affected by their pain. This study aimed to address this gap by developing MySpineData-Kids ("MiRD-Kids"), a tailored patient-reported questionnaire focusing on children with spinal pain in secondary care (Danish hospital setting).

View Article and Find Full Text PDF
Article Synopsis
  • Liver cancer is a major cause of cancer deaths, and using beta-emitting radionuclides in targeted treatments like Ho-hydroxyapatite (Ho-HA) is a promising approach.
  • The study estimated radiation absorbed doses of Ho-HA in the liver and other tissues using specific calculation methods, revealing that over 84% of the dose concentrated in liver tissue.
  • Ho-HA treatment allows for high doses to the tumor while minimizing exposure to healthy tissues, suggesting its potential effectiveness for liver cancer therapy.
View Article and Find Full Text PDF

Radiopharmaceutical therapy (RPT) is an emerging prostate cancer treatment that delivers radiation to specific molecules within the tumor microenvironment (TME), causing DNA damage and cell death. Given TME heterogeneity, it's crucial to explore RPT dosimetry and biological impacts at the cellular level. We integrated spatial transcriptomics (ST) with computational modeling to investigate the effects of RPT targeting prostate-specific membrane antigen (PSMA), fibroblast activation protein (FAP), and gastrin-releasing peptide receptor (GRPR) each labelled with beta-emitting lutetium-177 (Lu) and alpha-emitting actinium-225 (Ac).

View Article and Find Full Text PDF
Article Synopsis
  • Type 2 diabetes mellitus (T2DM) is a varied disease, and recent research suggests that new subgroup classifications can help evaluate the risk of diabetic complications, particularly diabetic kidney disease (DKD) in Chinese patients.
  • In a study involving 612 Chinese T2DM patients over 3.5 years, researchers used a two-step cluster analysis with five key parameters to categorize patients into four distinct groups based on their diabetes characteristics.
  • Findings revealed that certain groups, like the mild insulin resistance diabetes (MIRD) and severe insulin-deficient diabetes (SIDD), had higher risks of kidney disease progression compared to others, emphasizing the importance of these subgroup classifications in managing T2DM complications.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!